Advertisement

2015 Gastrointestinal Cancers Symposium

Highlights From the 2015 Gastrointestinal Cancers Symposium

The 2015 Gastrointestinal Cancers Symposium was held January 15 to 17. Direct your patients to www.cancer.net/blog to read the latest research on the treatment of colorectal cancer, including what it ...

breast cancer

Enzalutamide Shows Encouraging Activity in Triple‑Negative Breast Cancer

The androgen receptor inhibitor enzalutamide (Xtandi) showed encouraging activity as a single agent in advanced triple-negative breast cancer patients expressing the androgen receptor, according to an...

Pancreatic Cancer

Modified Nab-Paclitaxel/Gemcitabine in Pancreatic Cancer: Efficacious, Less Toxic, Less Costly

A less intensive regimen of nab-paclitaxel (Abraxane) plus gemcitabine appears to be as efficacious as the standard regimen in first-line treatment for metastatic pancreatic cancer, but less toxic and...

colorectal cancer

Observation Appropriate for Some Patients With Rectal Cancer Following Neoadjuvant Therapy

Some patients with rectal cancer who achieve a complete response to neoadjuvant chemoradiation therapy can be monitored for tumor recurrence and may never need surgery, according to a retrospective re...

pancreatic cancer

Pancreatic Cancer: Latest Drug Development Hits and Misses

Targeting one of the deadliest cancers and seeking to fill an unmet need, drug development in pancreatic cancer is an area of high interest. This was certainly the case at the 2015 Gastrointestinal Ca...

pancreatic cancer

FOLFIRINOX Plus Radiation Renders Some Locally Advanced Pancreatic Cancer Patients Resectable

Investigators from Moffitt Cancer Center in Tampa, Florida, have reported an approach to pancreatic cancer that downstages some locally advanced patients to borderline resectable status and achieves a...

gastroesophageal cancer

Radiotherapy Alone as Effective as Chemoradiation Therapy in Palliation of Dysphagia in Patients With Advanced Esophageal Cancer

Palliation of dysphagia associated with advanced esophageal cancer can be effectively accomplished with radiotherapy alone, without the addition of chemotherapy, according to a multinational phase III...

Skin Cancer
Gastrointestinal Cancer

Surgery Plus Immunotherapy Improves Survival in Melanoma Patients With Gastrointestinal Metastases

When melanoma patients develop metastases to the gastrointestinal (GI) tract or pancreas, resection of these lesions may improve survival, according to two single-institution studies presented at the ...

Colorectal Cancer

Ramucirumab Added to FOLFIRI Yields Results Similar to Bevacizumab or Aflibercept in Second‑Line Colorectal Cancer

The phase III international RAISE trial found that ramucirumab (Cyramza) extends survival when given with chemotherapy to metastatic colorectal cancer patients who progress on treatment,1 but some exp...

Neuroendocrine Tumors

Lanreotide Evaluated in Pancreatic Neuroendocrine Subgroup

The somatostatin analog lanreotide (Somatuline) depot extended the time to disease progression in patients with pancreatic neuroendocrine tumors, in a planned subgroup analysis of the CLARINET trial, ...

gastroesophageal cancer

Inhibiting the MET Pathway in Gastroesophageal Cancer: Hits and Misses

The MET pathway appears to be important in gastroesophageal cancers, but response to a targeted agent may depend on the class of drugs. A robust response to the novel small-molecule MET inhibitor AMG ...

hepatobiliary cancer

Targeting Biliary Tract Cancers Through Genomic Profiling

Biliary tract cancers are challenging, but a large genomic profiling study has identified potentially clinically relevant genomic alterations in up to two-thirds of patients.1 “The diverse landscape ...

Colorectal Cancer
Pancreatic Cancer
Gastrointestinal Cancer

New Data Reported in Colorectal, Gastric, and Pancreatic Cancers

The 2015 Gastrointestinal Cancers Symposium, held January 15–17 in San Francisco, attracted almost 4,000 attendees, who heard or viewed data from nearly 800 scientific abstracts and lectures. Here are...

colorectal cancer

Optimal Timing of Rectal Surgery: 60 Days or Less Post Chemoradiation Therapy

For the treatment of locally advanced rectal cancer, the optimal timing between the end of neoadjuvant chemoradiation therapy and surgical resection appears to be 60 days, according to an analysis of ...

supportive care

Many Cancer Patients at Risk for Hepatitis B Virus Reactivation

In 2015, no cancer patients should be cured of their malignancy only to die of reactivation of hepatitis B virus (HBV),” according to Anna S. Lok, MD, the Alice Lohrman Andrews Research Professor in H...

Advertisement

Advertisement



Advertisement

click me